3期临床-话题@MedSci

#3期临床#

90篇内容 | 4279人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1911288, encodeId=9bf519112881a, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=J Dermatolog Treat：利用第3期临床试验中患者水平的银屑病面积和严重程度指数评分来分析疾病活动和治疗效果, objectType=article, longId=723775, objectId=0fece2377517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fece2377517, replyNumber=0, likeNumber=150, createdTime=2023-01-06, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fece2377517, moduleTitle=J Dermatolog Treat：利用第3期临床试验中患者水平的银屑病面积和严重程度指数评分来分析疾病活动和治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fece2377517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911300, encodeId=cce7191130041, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=首个国产二价HPV疫苗3期临床结果发布：100%预防宫颈癌前病变, objectType=article, longId=737411, objectId=5c71e3741118, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c71e3741118, replyNumber=0, likeNumber=167, createdTime=2022-12-29, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c71e3741118, moduleTitle=首个国产二价HPV疫苗3期临床结果发布：100%预防宫颈癌前病变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c71e3741118)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911299, encodeId=59a8191129938, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！, objectType=article, longId=737158, objectId=579ee371587c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=579ee371587c, replyNumber=0, likeNumber=170, createdTime=2022-12-01, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=579ee371587c, moduleTitle=Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=579ee371587c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911297, encodeId=01e6191129ebd, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=FDA批准Buntanetap治疗帕金森病的3期临床试验, objectType=article, longId=734865, objectId=f9c7e3486590, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9c7e3486590, replyNumber=0, likeNumber=159, createdTime=2023-06-18, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9c7e3486590, moduleTitle=FDA批准Buntanetap治疗帕金森病的3期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9c7e3486590)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911292, encodeId=6436191129298, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=中国生物11价HPV疫苗预防宫颈癌3期临床试验已启动, objectType=article, longId=728562, objectId=661ee2856268, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=661ee2856268, replyNumber=0, likeNumber=0, createdTime=2023-02-21, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=661ee2856268, moduleTitle=中国生物11价HPV疫苗预防宫颈癌3期临床试验已启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=661ee2856268)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911286, encodeId=21d9191128664, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=NEJM：BioMarin的血友病AAV疗法3期临床试验结果发布，效果良好且持续, objectType=article, longId=301169, objectId=145e301169bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=145e301169bd, replyNumber=0, likeNumber=139, createdTime=2022-06-12, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=145e301169bd, moduleTitle=NEJM：BioMarin的血友病AAV疗法3期临床试验结果发布，效果良好且持续, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=145e301169bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911294, encodeId=0a6f1911294c0, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Muscle Nerve：间充质干细胞治疗ALS的3期临床试验失败, objectType=article, longId=730514, objectId=97f9e3051462, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97f9e3051462, replyNumber=0, likeNumber=184, createdTime=2022-12-23, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97f9e3051462, moduleTitle=Muscle Nerve：间充质干细胞治疗ALS的3期临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97f9e3051462)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911298, encodeId=c1411911298d0, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=半个世纪！辉瑞二价RSV疫苗RSVpreF的3期临床试验取得积极效果，拟向FDA递交申请, objectType=article, longId=737083, objectId=3dcee3708387, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dcee3708387, replyNumber=0, likeNumber=156, createdTime=2023-05-19, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dcee3708387, moduleTitle=半个世纪！辉瑞二价RSV疫苗RSVpreF的3期临床试验取得积极效果，拟向FDA递交申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dcee3708387)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911296, encodeId=33e919112968f, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=武田发布评估HYQVIA®用于慢性炎性脱髓鞘性多发性神经根神经病(CIDP)维持治疗的枢纽性3期临床试验阳性顶线结果, objectType=article, longId=733249, objectId=a155e3324911, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a155e3324911, replyNumber=0, likeNumber=152, createdTime=2023-02-21, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a155e3324911, moduleTitle=武田发布评估HYQVIA®用于慢性炎性脱髓鞘性多发性神经根神经病(CIDP)维持治疗的枢纽性3期临床试验阳性顶线结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a155e3324911)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911283, encodeId=b504191128367, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=EXPLORER-CN 3期临床试验：Mavacamten治疗有症状的梗阻性肥厚型心肌病在中国完成首例患者给药, objectType=article, longId=293854, objectId=d952293854cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d952293854cb, replyNumber=0, likeNumber=148, createdTime=2022-08-27, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d952293854cb, moduleTitle=EXPLORER-CN 3期临床试验：Mavacamten治疗有症状的梗阻性肥厚型心肌病在中国完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d952293854cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911290, encodeId=1ae319112901a, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=晚期食管癌一线治疗又添新突破：PD-1单抗「替雷利珠单抗」全球3期临床试验达到主要终点, objectType=article, longId=725482, objectId=de0ae25482c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de0ae25482c5, replyNumber=0, likeNumber=155, createdTime=2022-04-27, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de0ae25482c5, moduleTitle=晚期食管癌一线治疗又添新突破：PD-1单抗「替雷利珠单抗」全球3期临床试验达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de0ae25482c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911293, encodeId=9617191129346, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=J Clin Oncol：鲁卡帕利单药维持治疗新发卵巢癌的3期临床试验结果, objectType=article, longId=728879, objectId=1cfae28879bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cfae28879bb, replyNumber=0, likeNumber=0, createdTime=2022-07-01, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cfae28879bb, moduleTitle=J Clin Oncol：鲁卡帕利单药维持治疗新发卵巢癌的3期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cfae28879bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911291, encodeId=85fd1911291b4, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=维昇药业宣布其隆培促生长素中国3期临床试验达到主要终点，治疗效果优于生长激素日制剂, objectType=article, longId=727636, objectId=490ee276365c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=490ee276365c, replyNumber=0, likeNumber=122, createdTime=2022-09-25, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=490ee276365c, moduleTitle=维昇药业宣布其隆培促生长素中国3期临床试验达到主要终点，治疗效果优于生长激素日制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=490ee276365c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911295, encodeId=899d19112957d, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=新一代心肌肌球蛋白抑制剂aficamten在中国获得3期临床试验申请批准，用于治疗症状性梗阻性肥厚型心肌病, objectType=article, longId=730815, objectId=f09be30815b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f09be30815b3, replyNumber=0, likeNumber=168, createdTime=2022-08-27, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f09be30815b3, moduleTitle=新一代心肌肌球蛋白抑制剂aficamten在中国获得3期临床试验申请批准，用于治疗症状性梗阻性肥厚型心肌病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f09be30815b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911284, encodeId=a9571911284da, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Br J Dermatol：Baricitinib 3期临床试验中瘙痒和皮肤严重程度改善对特应性皮炎患者皮肤病生活质量指数的影响, objectType=article, longId=294697, objectId=b3fc29469e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3fc29469e5b, replyNumber=0, likeNumber=137, createdTime=2022-04-06, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3fc29469e5b, moduleTitle=Br J Dermatol：Baricitinib 3期临床试验中瘙痒和皮肤严重程度改善对特应性皮炎患者皮肤病生活质量指数的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3fc29469e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911285, encodeId=c8cd191128547, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Lancet Psychiatry：“社恐”和自闭症有救了？！3期临床提示新药安全但有效性存疑！, objectType=article, longId=295638, objectId=eca5295638b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eca5295638b9, replyNumber=0, likeNumber=122, createdTime=2022-02-15, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eca5295638b9, moduleTitle=Lancet Psychiatry：“社恐”和自闭症有救了？！3期临床提示新药安全但有效性存疑！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eca5295638b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911287, encodeId=6b1e191128e33, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=JR-141用于黏多糖贮积症II型全球3期临床试验取得进展, objectType=article, longId=302213, objectId=77b830221380, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77b830221380, replyNumber=0, likeNumber=142, createdTime=2022-10-21, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77b830221380, moduleTitle=JR-141用于黏多糖贮积症II型全球3期临床试验取得进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77b830221380)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911289, encodeId=29b1191128942, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=全球首个二价新冠疫苗2/3期临床结果公布，有效性是当前新冠疫苗的2倍多，秋季开打, objectType=article, longId=724738, objectId=d268e2473848, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d268e2473848, replyNumber=0, likeNumber=140, createdTime=2022-11-29, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d268e2473848, moduleTitle=全球首个二价新冠疫苗2/3期临床结果公布，有效性是当前新冠疫苗的2倍多，秋季开打, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d268e2473848)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911273, encodeId=300d19112e3be, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=JAMA Oncol：纳武利尤单抗（Nivolumab）联合伊匹木单抗（Ipilimumab）对比纳武利尤单抗治疗既往治疗过的IV期鳞状非小细胞肺癌的疗效：3期临床研究Lung-MAPS1400I, objectType=article, longId=214350, objectId=f3df214350a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3df214350a4, replyNumber=0, likeNumber=594, createdTime=2021-12-13, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3df214350a4, moduleTitle=JAMA Oncol：纳武利尤单抗（Nivolumab）联合伊匹木单抗（Ipilimumab）对比纳武利尤单抗治疗既往治疗过的IV期鳞状非小细胞肺癌的疗效：3期临床研究Lung-MAPS1400I, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3df214350a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911274, encodeId=394019112e40e, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效, objectType=article, longId=214456, objectId=4803214456af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4803214456af, replyNumber=0, likeNumber=175, createdTime=2021-11-03, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4803214456af, moduleTitle=Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4803214456af)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

3期临床

2020-05-29

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

J Dermatolog Treat：利用第3期临床试验中患者水平的银屑病面积和严重程度指数评分来分析疾病活动和治疗效果

2023-01-06

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

首个国产二价HPV疫苗3期临床结果发布：100%预防宫颈癌前病变

2022-12-29

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！

2022-12-01

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

FDA批准Buntanetap治疗帕金森病的3期临床试验

2023-06-18

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

中国生物11价HPV疫苗预防宫颈癌3期临床试验已启动

2023-02-21

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

NEJM：BioMarin的血友病AAV疗法3期临床试验结果发布，效果良好且持续

2022-06-12

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Muscle Nerve：间充质干细胞治疗ALS的3期临床试验失败

2022-12-23

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

半个世纪！辉瑞二价RSV疫苗RSVpreF的3期临床试验取得积极效果，拟向FDA递交申请

2023-05-19

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

武田发布评估HYQVIA®用于慢性炎性脱髓鞘性多发性神经根神经病(CIDP)维持治疗的枢纽性3期临床试验阳性顶线结果

2023-02-21

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

EXPLORER-CN 3期临床试验：Mavacamten治疗有症状的梗阻性肥厚型心肌病在中国完成首例患者给药

2022-08-27

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

晚期食管癌一线治疗又添新突破：PD-1单抗「替雷利珠单抗」全球3期临床试验达到主要终点

2022-04-27

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

J Clin Oncol：鲁卡帕利单药维持治疗新发卵巢癌的3期临床试验结果

2022-07-01

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

维昇药业宣布其隆培促生长素中国3期临床试验达到主要终点，治疗效果优于生长激素日制剂

2022-09-25

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

新一代心肌肌球蛋白抑制剂aficamten在中国获得3期临床试验申请批准，用于治疗症状性梗阻性肥厚型心肌病

2022-08-27

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Br J Dermatol：Baricitinib 3期临床试验中瘙痒和皮肤严重程度改善对特应性皮炎患者皮肤病生活质量指数的影响

2022-04-06

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Lancet Psychiatry：“社恐”和自闭症有救了？！3期临床提示新药安全但有效性存疑！

2022-02-15

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

JR-141用于黏多糖贮积症II型全球3期临床试验取得进展

2022-10-21

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

全球首个二价新冠疫苗2/3期临床结果公布，有效性是当前新冠疫苗的2倍多，秋季开打

2022-11-29

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

JAMA Oncol：纳武利尤单抗（Nivolumab）联合伊匹木单抗（Ipilimumab）对比纳武利尤单抗治疗既往治疗过的IV期鳞状非小细胞肺癌的疗效：3期临床研究Lung-MAPS1400I

2021-12-13

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Lancet respirat：同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效

2021-11-03

科室
- - 订阅+
  - 更多科室
工具
服务